Shares in FTSE 250 biotech firm Genus (LON:GNS) climbed by 5.05% to 4,529.56p (as of 12:45 GMT) after the firm confirmed that it continued to see strong trading during the final weeks of the half year ended 31st December. Revenues and adjusted pre-tax profits are both expected to be significantly above the comparable periods of 2019.
Management expect growth to slow during the second half, but believe that full-year performance will outpace current market expectations.